Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Print Print
Recommend this article Recommend this article
Save as favorites Save as favorites
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Volume 74, n° 2
pages 295-302 (février 2016)
Doi : 10.1016/j.jaad.2015.08.063
accepted : 23 August 2015
Original Articles
Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study
 

Liza Gill, BS a, Allison Zarbo, BA b, Prescilia Isedeh, MD c, Gordon Jacobsen, MS d, Henry W. Lim, MD c, Iltefat Hamzavi, MD c, ⁎
a College of Human Medicine, Michigan State University, East Lansing, Michigan 
b Wayne State University School of Medicine, Detroit, Michigan 
c Vitiligo Research and Treatment Center, Department of Dermatology, Henry Ford Hospital, Detroit, Michigan 
d Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan 

∗Reprint requests: Iltefat Hamzavi, MD, Department of Dermatology, Henry Ford Hospital, 3031 W Grand Blvd, Suite 800, Detroit, MI 48202.
Abstract
Background

Few large-scale studies have quantified the burden of comorbid autoimmune diseases in patients with vitiligo.

Objective

We sought to determine the prevalence of comorbid autoimmune diseases in patients with vitiligo.

Methods

We conducted a manual chart review on a cohort of 1873 patients with vitiligo seen between January 2002 and October 2012 at the Henry Ford Health System in Detroit, MI. Patients were excluded if they had fewer than 2 dermatology notes (N = 595) or if they were never given a diagnosis of vitiligo by a dermatologist (N = 180).

Results

Of 1098 patients with vitiligo, nearly 20% had at least 1 comorbid autoimmune disease. Compared with the general US population, we found a higher prevalence of thyroid disease (12.9%, P  < .001), alopecia areata (3.8%, P  < .001), inflammatory bowel disease (0.9%, P  = .046), pernicious anemia (0.5%, P  = .007), systemic lupus erythematosus (0.3%, P  = .048), Guillain-Barre syndrome (0.3%, P  < .001), discoid lupus (0.2%, P  = .003), linear morphea (0.2%, P  < .001), myasthenia gravis (0.2%, P  = .002), and Sjögren syndrome (0.2%, P  = .011).

Limitations

The study lacked a control group. This was a single-institution study with possible selection bias, and thus the findings may not be representative of the overall population of patients with vitiligo.

Conclusions

We observed a high prevalence of comorbid autoimmune diseases in patients with vitiligo and report several new associations.

The full text of this article is available in PDF format.

Key words : alopecia areata, associations, autoimmune disease, comorbidities, prevalence, thyroid disease, vitiligo

Abbreviations used : BSA, IBD, SLE, TPO, TSH, T1DM


OutlineMasquer le plan
Methods  (+)
Results  (+)
Discussion  (+)

 Funding sources: None.
 Conflicts of interest: None declared.



© 2015  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline